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Background: Successful antiretroviral therapy (ART) has dramatically reduced mortality among HIV-infected
children. However, there is growing concern about long-term effects associated to ART. The aim of this study was
to determine the prevalence of metabolic abnormalities in a cohort of perinatally HIV-infected adolescents and
young adults and to identify associated factors.
Methods: We present results from a cross-sectional analysis including individuals 12 to 20 years of age, from a
prospective, longitudinal cohort of perinatally-acquired HIV-infected children, adolescents and young adults in
Madrid. Clinical and immunological data were recorded and complete lipid and glycemic profiles were determined.
Results: Ninety-nine adolescents were included, with a median age of 15.3 years [13.6-16.7]. Patients with abnormal
levels of lipids were as follows: 27.2% total cholesterol ≥200 mg/dl, 25.9% LDL cholesterol (LDL-c) ≥ 130 mg/dl,
14.1% HDL-C < 35 mg/dl and 39.8% triglycerides ≥ 150 mg/dl. Current use of protease inhibitors (PI) was associated
with higher triglyceride values (p = 0.022). Four (4.6%) patients showed fasting glucose≥ 100 mg/dl and 30.6%
presented with insulin resistance (IR) (HOMA-IR over the 90th centile). In the multivariate logistic regression analysis
adjusted for sex, age, weight, Tanner stage, protease inhibitors (PI) and nucleoside reverse transcriptase inhibitors (NRTI)
treatment length and CD4 nadir, IR was associated with higher waist circumference Z score; OR: 3.92(CI95%: 1.15-13.4)
(p = 0.03).
Conclusion: There was a high prevalence of insulin resistance and lipid abnormalities in this cohort of
perinatally-acquired HIV-infected adolescents. A simple clinical measurement like waist circumference Z score
might be a reliable marker and predictor of insulin resistance in these patients.
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Life expectancy has dramatically improved in HIV-infected
children since the introduction of highly active antiretro-
viral therapy (HAART). However, several studies have re-
ported a high prevalence of metabolic disorders in this
unique population, and there is growing concern about the* Correspondence: danielblazquezgamero@gmail.com
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lipidemia and insulin resistance (IR) have been widely de-
scribed among ART-treated children and adolescents,
although the prevalence of these disorders differs signifi-
cantly among studies [1-4].
In the general population, metabolic disorders during
childhood, especially dyslipidemia and IR, have been asso-
ciated with early development of cardiovascular disease
(CVD) [5]. HIV-infected subjects are known to be a popu-
lation at high risk for premature atherosclerosis [6,7] and
in fact, previous studies have already demonstratedal. This is an Open Access article distributed under the terms of the Creative
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infected children and adolescents [8-10]. Although the
underlying mechanisms are not well understood, ART-
mediated dyslipidemia has been proposed as a deter-
minant factor [11]. It has been shown that HIV can by
itself decrease the insulin sensitivity of peripheral tis-
sues [12] and a close association between glucose toler-
ance and coronary atherosclerosis has been well
established [13]. Despite the growing concern regard-
ing the increased risk of metabolic complications and
early cardiovascular disease associated to HIV infection,
no specific preventive measures have been defined. This
lack of preventive measures is of particular relevance for
the very unique population of perinatally-acquired HIV-
infected patients, especially since these individuals have a
lifelong exposure to ART and the deleterious effects of
chronic inflammation associated to the infection. The aim
of this study was to assess the prevalence of metabolic ab-
normalities, including dyslipidemia and insulin resistance,
within a cohort of perinatally-acquired HIV-infected ado-
lescents, and to determine possible associated clinical fac-
tors that could potentially be used to identify subjects at
increased risk for premature cardiovascular disease.
Methods
Study design and eligibility criteria
We present results from a cross-sectional analysis
performed in 2009, within a prospectively- followed
CoRISpe-Madrid Cohort of Pediatric HIV-infected
children and adolescents that started on 2002.
Inclusion criteria included: age between 12 and 20 years
old, perinatally-acquired HIV infection, follow-up at one
of six participating centers and at least one visit during
study period with anthropometric measurements and fast-
ing blood samples available.
The study was approved by the Ethics Committee and
Clinical Research Review Board of the participating hos-
pitals, and written informed consent was obtained from
the parents or legal guardians or from the patients when
they were 18 years old or over.
Clinical assessment and anthropometric measurements
Clinical data were recorded at the time of visit and in-
cluded gender, age, ethnicity, Center for Disease Control
(CDC) pediatric HIV disease stage, type of treatment and
Tanner stage. All patients underwent physical examin-
ation. Height and weight were measured and body mass
index (BMI) was calculated. Waist and hip circumferences
were measured using a plastic non-stretchable tape, at the
navel during inspiration and at the maximum protrusion
of the gluteal region, respectively. All anthropometric
measurements were adjusted using z score according to
the age and gender, based on referenced Spanish growth
charts [14,15]. Immuno-virological details and data onprevious ART history were collected from the CoRISpe-
Madrid Cohort of Pediatric HIV-infected children and ad-
olescents database [16].
Laboratory analyses
Fasting blood samples were drawn from all participants for
real-time measurements of glycemic and lipid profile, deter-
mined at the different participating hospitals using standard
enzymatic methods. Determinations included insulin and
glucose levels, total cholesterol, high-density lipoprotein
cholesterol [HDL-c], low-density lipoprotein cholesterol
[LDL-c] and triglycerides. Simultaneously, plasma HIV-1
viral load (VL) was quantified using the Cobas TaqMan
HIV-1 assay (Roche Diagnostics Systems, Inc, Branchburg,
NJ) with a detection limit of 50 copies/mm3. Absolute
count and percentage of CD4 and CD8 T-cell were con-
comitantly measured using flow cytometry.
According to the American Diabetes Association, im-
paired fasting glucose was defined as glucose ≥ 100 mg/dl
[17]. Insulin resistance was calculated using the homeosta-
sis model assessment of insulin resistance (HOMA-IR =
fasting insulin (microU/ml) x fasting glucose (g/dl)/405)
[18]. As no pediatric reference values are available for
HOMA-IR and/or fasting insulin levels, we used the cut-off
points defined by García-Cuartero et al. [19] as the 90th
percentile adjusted for sex and Tanner stage for pediatric
reference population in Spain. Hypertriglyceridemia was
defined by the presence of plasma triglycerides ≥ 150 mg/dl,
hypercholesterolemia by total cholesterol ≥ 200 mg/dl, in-
creased LDL-c ≥ 130 mg/dl, and low HDL-c if levels <
35 mg/dl based on current recommendations of the Ameri-
can Academy of Pediatrics [20].
Statistical analyses
Continuous variables were expressed as median and
interquartile range (IQR), and categorical variables as
counts and percentages. Mann–Whitney U test were
used for independent two-group comparisons in con-
tinuous variables and χ2 or Fisher’s exact test were used
to compare categorical variables.
Adjusted analyses: All variables independently associ-
ated were included in the multivariate analysis, as well as
those variables considered clinically relevant. Multivariate
logistic regression model was used to study the association
of ddI exposure with increased LDL-c, adjusted for poten-
tial confounders including age, sex, Tanner stage, weight
PI and NRTI treatment length and CD4 nadir. Multivari-
ate logistic regression model was used to study the associ-
ation of abdominal circumference Z score with increased
HOMA-IR, adjusted for potential confounders including
age, sex, Tanner stage, weight, PI and NRTI treatment
length and CD4 nadir. Interactions between predictor var-
iables were evaluated but no significant results were
found, and were not included in the model. All statistical
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SPSS, Chicago, IL, USA).
Results
Study population and clinical characteristics
During the study period there were 214 patients
followed up in CoRISpe-Madrid Cohort of Pediatric
HIV-infected children and adolescents. One hundred
and four adolescents and young adults who met inclu-
sion criteria were eligible, and five patients refused to
participate in the study. Ninety-nine were enrolled, with
a median age of 15.3 years [13.6-16.7] and 57.6% (n = 57)
were female. Main characteristics at the time of the as-
sessment are shown in Table 1. At the time of inclusion
adolescents were either receiving HAART (n =92;
92.9%) or off therapy (7%). Twenty-eight percent of indi-
viduals had received 5 or more different ART regimens.
Only one patient was receiving lipid-lowering therapy
(ezetimibe) at the time of the study. Seven patients pre-
sented with hepatitis C virus co-infection.
Adherence was assessed by physician’s interview in all
patients at the time of clinical visit.
Lipid abnormalities and association with clinical variables
Twenty-five ( 25/90 27.2%) children had cholesterol levels
over 200 mg/dl, 22/85 (25.9%) LDL-c over 130 mg/dl, 13/
92 (14.1%) HDL-c under 35 mg/dl and 39/98 (39.8%) tri-
glycerides over 150 mg/dl. Median values for total choles-
terol, LDL-c, HDL-c cholesterol, triglycerides, glucose,
insulin and HOMA are shown in Table 2.
We first explored factors associated with the presence of
increased LDL-c. In the univariate analysis, the presence
of LDL-c > 130 mg/dl was associated with ddI exposure
(p = 0.027) but no association with stavudine (d4T) (p = 0.4)
or PI (p = 0.179) exposure was found. Children with in-
creased LDL-c presented with higher CD4 count (852 [IQR:
714.8-1124.8] vs 625,0 [490–854], p = 0.008). In the multi-
variate logistic regression model, adjusting by sex, age, PI
and NRTIs exposure, and CD4 count, the association between
current ddI use and increased LDL-c levels did not reach stat-
istical significance (OR=3.44 (CI95%: 0.976-12.12), p = 0.055).
Regarding HDL-c, low HDL-c levels were associated with
male sex (p = 0.035) and presence of larger abdominal
circumference: (78 cm [73.8-82.2] vs 72.75 cm [68.2-79.3];
p = 0.04), but no association with treatment was found.
Children with hypertriglyceridemia presented with
higher CD4 count (831 [586–1115.2] vs. 660 [477–900],
p = 0.026) and higher levels of triglycerides were also
found in children receiving PI therapy (128.5 mg/dl
[88.7-196.7] vs. 85 mg/dl [57–167.5], p = 0.022).
Insulin and HOMA
A total of 26 (30.6%) children presented with insulin levels
and HOMA-IR values above the 90th centile, adjusted bysex and Tanner stage. However, only 4 (4.6%) adolescents
had a fasting glucose greater than 100 mg/dl.
In the univariate analysis the presence of elevated
HOMA-IR values was associated with greater waist cir-
cumference Z score (0.31 [IQR: 0.31-1.13] vs. 0 [−0.67-
0.31], (p = 0.016) (Figure 1). Children with elevated
HOMA-IR values had higher nadir CD4 count and per-
centage; 363 CD4 mm [IQR: 170–556.8] vs. 197 [88–
391]; (p = 0.015) and 17.5% [10.8%-23.8%] vs. 12% [4%-
16%]; (p = 0.003) respectively. No association with
current or previous ART exposure, ethnicity, BMI, weight,
height, waist-to-hip ratio, current CD4 count or CDC
pediatric HIV disease stage was found. No association
with elevated HOMA-IR was found in children with hepa-
titis C virus co-infection (p = 0.193).
In the multivariate logistic regression analysis, higher
HOMA-IR values were associated with higher waist cir-
cumference Z score OR: 3.92(CI95%: 1.15-13.4) (p = 0.03),
adjusted for sex, age, weight, Tanner stage and PI and NRTI
treatment length, and CD4 nadir (Table 3).
Discussion
In this cross-sectional study in a cohort of perinatally-
acquired HIV-infected adolescents and young adults on
ART, we found a high prevalence of abnormal levels of
lipids in serum and insulin resistance. Up to 40% of the
study participants showed hypertriglyceridemia, 27.2%
increased levels of total cholesterol, 25.9% elevated LDL-
c cholesterol and 14.1% of the subjects had low HDL-c.
In addition, a third of the study participants had insulin
and HOMA-IR levels above the 90th centile. PI exposure
was associated with hypertriglyceridemia, but not with
increased levels of total cholesterol, LDL-c or HDL-c,
and no association was found with the presence of insu-
lin resistance. A strong correlation was seen between
HOMA-IR values and Z score -adjusted waist circumfer-
ence; this correlation remained significant after adjust-
ment by potential confounders.
HIV-infected children can expect to live for many
years since the introduction of HAART. However, sev-
eral studies have reported a high prevalence of metabolic
disorders in this unique adolescent population and there
is growing concern about the long-term complications
in children with lifelong exposure to ART. Dyslipidemia
and insulin resistance have been widely described among
ARV-treated children and adolescents, although the
prevalence of these disorders differs significantly among
studies [1,2,21,22]. The use of diverse ART regimens ac-
cording to different national guidelines and availability
may explain some of the differences found. However,
socio-demographic factors, and especially factors related
to diet, may also be partially responsible for this diver-
gence in results. In the Spanish pediatric population, the
reported prevalence of hypercholesterolemia(>200 mg/
Table 1 Main characteristics of study participants
Variable N = 99






















Weight (kg) 51.1 [44.7-59.2]
Weight Z score −0.2 [−0.79-0.76]
Height (cm) 160 [153.5-166.9]
Height Z score −0.03 [−1-0.7]
BMI 19.9 [18.3-22.3]
Age at menarche (years) 12.0 [11.7-13.0]
Treatment
HAART 92 (92.9)
No treatment 7 (7.1)
Total ARV exposure (years) 11.4 [9.1-12.8]
HAART exposure (years) 9.4 [6.7-10.7]
PI exposure (months) 90.4 [44.1-127.8]
NNRTI exposure (months) 39.8[3.3-85.7]
Type of treatment
2 NRTIs + 1 PI 35 (38.1)
2 NRTIs + 1 NNRTI 28 (30.4)
2 NRTIs + 1 PI +1 NNRTI 21 (22.8)
Other 8 (8.7)
Viral load (copies/ml) 50 [50–200]
Viral load (<50 copies/ml) 66 (66.7)
Table 1 Main characteristics of study participants
(Continued)
CD4 count (cs/mm3) 737.0 [503.8-975.5]
CD4 % 33 [25.4-38.5]
CD4 nadir (cs/mm3) 252 [102–442]
Continuous variables were expressed as median and interquartile range (IQR)
and categorical variables were expressed as counts (N) and percentages (%).
Abbreviations: IQR interquartile range, CDC centers for disease control and
prevention, HAART highly active antiretroviral therapy, ARV antiretroviral,
BMI body mass index, NRTI nucleoside reverse transcriptase inhibitors, NNRTI
non-nucleoside analog, PI protease inhibitor.
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vated LDL-c (>130 mg/dl) and, in the Madrid area, 7.7%
of children presented with triglycerides over 100 mg/dl
[23]. We found similar rates of hypercholesterolemia
(27.2%) and elevated LDL-c (14.1%), but a higher rate of
hypertriglyceridemia (39,8%) in perinatally-acquired
HIV-infected adolescents and young adults.
Recently, data from a cross-sectional analysis in the
Spanish cohort of HIV-infected children have been pub-
lished. Dapena et al. [2] found similar lipid abnormalities
in Spain, as well as increased rate of insulin resistance
(19.9%) compared to other studies. The prevalence of IR
in our study (30.6%) is even higher than the overall rate in
this Spanish cohort of HIV-infected children. Results from
studies addressing this issue in different settings have de-
scribed much lower prevalence of IR (6,5-6,8%) in HIV-
infected children [4,24]. In contrast, studies including
perinatally-acquired HIV-infected adolescents and young
adults evidence higher rates of IR (15.2 -52%) [2,21,25,26].
The fact that the results presented here correspond to aTable 2 Main metabolic results
Variable
Total cholesterol (mg/dl) 173.5 [IQR:151.8-202.5]
Total cholesterol > 200 mg/dl 25/90 (27.2)
HDL-cholesterol (mg/dl) 47.0 [41.3-59.8]
HDL-c < 35 mg/dl 13/92 (14.1)
LDL-cholesterol (mg/dl) 98.0 [79.3-128.3]
LDL-c > 130 mg/dl 22/85 (25.9)
Triglycerides (mg/dl) 116.0 [76.0-194.5]
Triglycerides > 150 mg/dl 39/98 (39.8)
Fasting glycemia (mg/dl) 87.0 [82–93.5]
Fasting hyperglycemia (>100 mg/dl) 4/87 (4.6)
Insulin (U/ml) 12.2 [8.3-22.8]
Hyperinsulinemia 26/85 (30.6)
HOMA 2.7 [1.8-4.7]
Insulin resistance 26/85 (30.6)
Continuous variables were expressed as median and interquartile range (IQR) and
categorical variables were expressed as counts (N) and percentages (%).
Abbreviations: IQR interquartile range, HDL-c high-density lipoprotein cholesterol,
LDL-c low-density lipoprotein cholesterol, HOMA homeostasis model assessment.
Figure 1 Waist circumference Z score in children with and without elevated HOMA-IR values according to sex and Tanner stage.
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IR, raising concerns as they suggest that the prevalence of
these disorders among vertically HIV-infected individuals
might increase as the population grows up.
In this study, IR was associated with the presence of
higher waist circumference Z score values, both in the
univariate and multivariate analysis. If these findings are
further confirmed, a simple anthropometric measurement
(such as waist circumference) could be used to detect
those children with increased risk for metabolic abnormal-
ities. We believe this finding could be extremely helpful,
especially in resource-poor settings. An association be-
tween waist circumference and increased cardiovascular
risk has been previously described in otherwise healthy
adults [27,28]. Data on children and adolescents are,Table 3 Multivariate logistic regression model for insulin
resistance and abdominal Z score adjusted for sex, age,
weight, Tanner stage, CD4 nadir and PI and NRTI
treatment length
OR CI95% P value
Sex 0.87 0.19 4.3 0.891
Age 1.72 0.97 3.01 0.056
Weight 0.98 0.89 1.08 0.752
Tanner stage 0.30 0.13 0.71 0.006
PI treatment length 0.99 0.98 1.0 0.258
NNRTI treatment length 0.99 0.97 1.005 0.158
CD4 nadir 1.05 0.96 1.153 0.252
Abdominal circumference Z score 3.92 1.15 13.4 0.003
Abbreviations: HOMA homeostasis model assessment, PI protease inhibitor,
NNRTI non-nucleoside reverse transcriptase inhibitors.however, scarce [29,30]. In the special setting of pediatric
HIV infection, associations between waist circumference
and IR and other metabolic disorders have been studied,
but results have been inconclusive. In the study by Geffner
et al. higher total waist circumference (as well as other an-
thropometric measurements like BMI, waist-to-hip ratio
and weight Z score) was associated with IR [26], but in an-
other study including only adolescents, waist-to-hip ratio
remained the only independent predictor of IR (HOMA-
IR >4) in the multivariate logistic regression model [31].
Aldrovandi et al. found no statistically significant differ-
ences in waist circumference Z score in HIV-positive chil-
dren (on PI or NNRTI treatment) compared to uninfected
children and adolescents [1]. Interestingly in this study,
HIV-infected children presented with higher HOMA-IR
median values despite lower height, weight and BMI Z
scores than healthy children [1]. Recently, the study by
Hazra et al. found no relationship between anthropomet-
ric measurements and the presence of IR [4]. The fact that
most studies used a single HOMA-IR cutoff value to de-
fine IR may explain most of the differences found among
these studies. HOMA-IR reference values are not well de-
fined in childhood and they are known to be influenced by
age, gender and Tanner stage. In fact, Geffner et al. found
that children at Tanner stage 5 were 4 times more likely to
be diagnosed with IR compared to children at Tanner
stages 1–3 [26]. In our study, in an attempt to more accur-
ately identify patients at higher risk of IR, elevated
HOMA-IR was defined according to the 90th centile of the
Spanish pediatric population, using a specific cutoff value
according to gender and Tanner stage [19], and, therefore,
we believe our results may be more accurate. Abdominal
Blázquez et al. BMC Infectious Diseases  (2015) 15:119 Page 6 of 7circumference also changes significantly from children to
adolescents and young adults. Interestingly, Miller et al.
found that HIV-infected children presented with similar
total waist circumference compared to healthy controls
despite having lower weight, height and BMI Z scores [3].
These findings suggest a disproportionate higher waist cir-
cumference in HIV-infected children due to a fat redistri-
bution. We think that it is of paramount importance to
use waist circumference Z score adjusted by age and sex
[15] when anthropometric evaluation is performed in
HIV-infected children.
In this study children with IR presented with higher
CD4 nadir. Previous studies have also shown that HIV-
infected children with IR are not characterized by a very
low nadir CD4 (absolute and percent) [26], suggesting that
the development of IR might not be related to the extent
of immunodeficiency, as has been suggested for other
complications associated to HIV such as cardiovascular
risk [32]. On the other hand, children with hypertriglyc-
eridemia or increased LDL-c values showed higher CD4
count at the time of the assessment, which could be ex-
plained by better adherence to ARV treatment, similar to
other studies previously published [2], although this issue
has not been specifically addressed in our study.
This study has the inherent limitations of a cross-
sectional design, and no causal inferences can be made.
The rather small sample size of the study obviously limits
our ability to measure the contribution of particular ARV
regimens on the development of metabolic abnormalities.
Socioeconomic status of the family was not investigated in
this study, and this fact should have some relation with
nutrition and health habits and, therefore, with metabolic
profiles. Oral glucose tolerance was not performed in this
study. We use the ADA’s cutoff for impaired fasting glu-
cose (100 mg/dl), so it should be noted that other organi-
zations define the impaired fasting glucose cutoff at
110 mg/dl. A lower cutoff for IFG could overestimate the
prevalence, but only 4 patients were over 100 mg/dl and
insulin resistance definition was not influenced by IFG
cutoff. Lastly, the absence of a control group of uninfected
children constitutes a main limitation of this study. In
order to overcome this fact, a referenced-based population
has been used for comparison, and parameters have been
adjusted according to age, sex and Tanner stage.
Conclusions
Despite the unquestionable benefit of the ARV treatment
for vertically-acquired HIV-infected subjects, much atten-
tion has to be paid to long-term complications of a lifelong
exposure to treatment in this unique population. Very high
prevalence of insulin resistance and lipid abnormalities has
been found in this study as well as in other studies, and
specific preventive measures for this population are still
lacking. If the results presented here are further confirmed,a simple measurement of waist circumference might be a
reliable marker of IR in HIV-infected adolescents, which
could help to easily detect those patients with an increased
risk of metabolic disorders and cardiovascular disease in
the future.
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